The precise determination of the subset of patients with luminal carcinomas (ER+/PR+/HER2−) who are suitable for chemotherapy (associated with hormone therapy) is the main issue, and the assessment of IK has shown promising preliminary data with regard to these issues (34,35). This evidence concerns the gene PGR and carcinoma.